Adapt AO outperforms conventional lens

Article

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL.

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL, according to Ann Haustermans, Belgium.

The multicentre, prospective, intra-individual, comparative study enrolled 69 patients requiring bilateral cataract surgery. One eye of each subject received the Adapt AO and the other the spherical Akreos Adapt lens. Follow-up data was collected at one and three months and one and two years, and patients completed a questionnaire assessing their quality of vision at three months.

At one-month follow-up, the Adapt AO performed significantly better in low contrast UCVA (p=0.03) and BCVA (p=0.047). It was also found to perform better than the spherical Adapt at all spatial frequencies in photopic contrast sensitivity and at 1, 5 and 6 cpd in mesopic contrast sensitivity. At three-months follow-up, the lenses performed equally but at one year the Adapt AO performed better in high contrast UCVA and BCVA.

Dr Haustermanns concluded that the aspheric Akreos Adapt AO lens offers better optical performance than the conventional spherical Adapt IOL.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.